Category - Developments

Developments

Aytu signs agreement to commercialize Exxua for MDD

Aytu BioPharma (ASDAQ: AYTU) announced that it has signed an exclusive agreement with closely held Fabre-Kramer Pharmaceuticals to commercialize Exxua—extended-release antidepressant tablets—in the U.S. market for major...

June 9, 2025

Developments

Vaccines publishes key benefits of PharmaJet Tropis ID vaccine over IM SoC

Closely held PharmaJet announced that the results of an implementation research study—titled Evaluating the impact of needle-free delivery of inactivated polio vaccine on Nigeria’s routine immunization program: An...

June 5, 2025

Developments

Perimeter launches OCT-Tissue Registry to power AI and imaging innovation

Perimeter Medical Imaging AI (TSXV: PINK; OTCQX: PYNKF) has announced the launch of its optical coherence tomography (OCT)-Tissue Surveillance Registry—a database designed to collect thousands of images from surgical...

June 4, 2025

Developments

Leonard Wheeler, former NFL player, named global ambassador for Profound’s TULSA-PRO

Profound Medical (NASDAQ: PROF; TSX: PRN) today announced that it has entered into a consulting agreement with Leonard Wheeler—former NFL player, entrepreneur, author, corporate consultant, co-executive director of the...

June 4, 2025

Developments

Defence opens first U.S. laboratory

Defence Therapeutics (CSE: DTC; OTCQB: DTCFF; FSE: DTC) announced that it has opened its first U.S.-based laboratory in the Boston-Cambridge area. According to Defence, the new laboratory will allow the company to...

June 2, 2025

Developments

atai and Beckley to combine establishing market leader in psychedelic mental health therapies

atai Life Sciences (NASDAQ: ATAI) and closely held Beckley Psytech announced a definitive agreement to combine in an all-share transaction subject to Phase 2b success criteria of BPl-003 in patients with treatment...

June 2, 2025

Developments

Genflow and CER agree to long-term R&D collaboration

Genflow Biosciences (LSE:GENF; OTCQB:GENFF) has announced the signing of a master service agreement (MSA) with closely held CER Groupe—a long-standing partner—to strengthen long-term research and development (R&D)...

May 28, 2025

Developments

NeoGenomics introduces PanTracer genomic profiling tests at ASCO 2025

NeoGenomics (NASDAQ: NEO) has announced that it will debut its PanTracer Family genomic profiling tests for advanced solid tumors at the 2025 American Society of Clinical Oncology (ASCO) in Chicago May 30—June 3, 2025...

May 28, 2025

Developments

Perimeter partners with Intermountain Health to study benefits of using OCT and AI to reduce cancer reoperations

Perimeter Medical Imaging AI (TSXV: PINK; OTCQX: PYNKF) has announced that it has entered into a development support agreement with Intermountain Health, creating the framework for the two organizations to partner on a...

May 23, 2025

Developments

FDA clears Quoin’s second QRX003 NS pivotal study

Quoin Pharmaceuticals (NASDAQ: QNRX) announced that the FDA has provided clearance to initiate a second Netherton Syndrome (NS) clinical pivotal study—CL-QRX003-002, for Quoin’s lead product QRX003. According to Quoin...

May 22, 2025

Category - Developments

Subscribe